Despite two decades of intensified research to understand and cure tuberculosis disease,
biological uncertainties remain and hamper progress. However, owing to collaborative …

Drug-resistant tuberculosis (TB) is estimated to cause 13% of all antimicrobial resistance-
attributable deaths worldwide and is driven by both ongoing resistance acquisition and …

Background In patients with rifampin-resistant tuberculosis, all-oral treatment regimens that
are more effective, shorter, and have a more acceptable side-effect profile than current …

Background The bedaquiline–pretomanid–linezolid regimen has been reported to have
90% efficacy against highly drug-resistant tuberculosis, but the incidence of adverse events …

The WHO Consolidated Guidelines on Tuberculosis (TB), Module 4: Treatment-Drug-
Resistant Tuberculosis Treatment 2022 update informs health care professionals in Member …

Mycobacterium tuberculosis (Mtb) is the causative agent of tuberculosis, an infectious
disease with one of the highest morbidity and mortality rates worldwide. Leveraging its …

Tuberculosis (TB) drug discovery and development has undergone nothing short of a
revolution over the past 20 years. Successful public–private partnerships and sustained …

Over the past 2000 years, tuberculosis (TB) has claimed more lives than any other infectious
disease. In 2020 alone, TB was responsible for 1.5 million deaths worldwide, comparable to …

Antimicrobial resistance is a major public health problem globally. Likewise, forms of
tuberculosis (TB) resistant to first-and second-line TB medicines present a major challenge …

Background The STREAM stage 1 trial showed that a 9-month regimen for the treatment of
rifampicin-resistant tuberculosis was non-inferior to the 20-month 2011 WHO-recommended …